Metagenomi Therapeutics, Inc. Annual Report - A Year in Review

Understanding a company like Metagenomi Therapeutics can be complex, but this summary aims to demystify its performance over the past year. We'll explore its operations, financial health, key achievements, challenges, and future prospects, providing a clear picture for investors considering this innovative biotechnology firm.

Key Developments This Year (Fiscal Year Ended December 31, 2025)

This report covers Metagenomi's activities and financial standing for the fiscal year that concluded on December 31, 2025. Here are the standout developments:

• Public Debut: Metagenomi achieved a significant milestone with its Initial Public Offering (IPO) in February 2024. The company officially became publicly traded on The Nasdaq Global Select Market under the ticker symbol MGX, making its shares available to the general public. The IPO provided substantial capital to advance its research and development efforts.
• Growing Strategic Partnerships: For a biotechnology company, collaborations are vital, bringing in funding, shared expertise, and accelerating scientific progress. Metagenomi actively pursued strategic alliances:
  • Metagenomi partnered strategically with Moderna to develop in vivo gene editing therapies using its proprietary gene editing systems.
  • Ongoing agreements include partnerships with Ionis Pharmaceuticals (initiated November 2022) for gene editing programs targeting neurological and neuromuscular diseases, and AffiniT Therapeutics (dating back to June 2022) for gene-edited T-cell therapies in cancer.
  • In September 2025, Metagenomi secured a license agreement with Acuitas Therapeutics, gaining access to Acuitas' lipid nanoparticle (LNP) technology, which is crucial for delivering gene editing therapies.
• Early-Stage Company Status: Metagenomi is currently classified as a "non-accelerated filer," a "smaller reporting company," and an "emerging growth company." These classifications indicate that Metagenomi is a relatively new and growing company, benefiting from certain (often less stringent) reporting requirements compared to larger, more established corporations.
• Market Value Snapshot: As of June 30, 2025, the market value of its common stock held by non-affiliates (representing shares available to the general public) was approximately $50.9 million. This valuation positions Metagenomi as a "small-cap" company within the stock market.
• Customer Concentration to Watch: Metagenomi reported that a significant portion of its revenue and accounts receivable (money owed to the company) originated from a limited number of key customers (identified as "Customer A" and "Customer B" in the filing). This customer concentration presents a risk; a reduction in business or financial difficulties experienced by a major customer could significantly impact Metagenomi's income.

Financial Performance (Income Statement Snapshot)

This section provides insight into Metagenomi's revenue and expenses, detailing its earnings and expenditures over the past two years.

• Revenue: Metagenomi generates revenue primarily through its collaboration agreements.
  • In 2025, total revenue reached $25.0 million, a modest increase from $20.0 million in 2024. This growth reflects progress in collaboration agreements and the recognition of deferred revenue.
• Research & Development (R&D) Expenses: As a biotechnology company, R&D represents Metagenomi's largest expenditure, fueling the discovery and development of new therapies.
  • R&D expenses rose to $95.0 million in 2025 from $80.0 million in 2024. This increase aligns with the company's strategy to advance its gene editing programs and expand its pipeline.
• General & Administrative (G&A) Expenses: These expenses cover executive salaries, legal fees, accounting, and other overhead costs.
  • G&A expenses were $17.9 million in 2025, slightly down from $18.1 million in 2024.
• Net Loss: As Metagenomi remains in the development phase and invests heavily in R&D, it continues to operate at a loss.
  • Metagenomi's net loss increased to $87.9 million in 2025 from $78.1 million in 2024. This larger loss primarily resulted from increased R&D spending, despite a modest rise in revenue.

Cash Flow & Financial Health

This year's report provides a clearer understanding of Metagenomi's financial health, particularly its cash utilization and generation.

• Cash Reserves: As of December 31, 2025, Metagenomi held $160.8 million in total liquid assets (cash, cash equivalents, and marketable securities), a significant decrease from $248.3 million at the end of 2024. This reduction primarily reflects the use of marketable securities to fund operations.
• Cash Runway: Based on current plans, Metagenomi estimates its cash will cover day-to-day business costs and capital expenditures for at least the next 12 months, commonly referred to as its "cash runway."
• Future Funding Needs: Despite its current cash position, Metagenomi anticipates requiring additional funding in the future. This is typical for biotechnology companies in the research and development phase. Future funding will support ongoing treatment development, patent protection, technological advancements, and scientific hiring. Should any treatments gain approval, substantial capital will also be necessary for manufacturing, sales, and marketing.
  • Potential Funding Sources: Potential funding sources include issuing more shares (which could dilute existing shareholder ownership), incurring debt (potentially with restrictive covenants), or expanding partnerships (which might involve ceding rights to technology or future profits).
• Overall Cash Flow – A Closer Look: While total liquid assets decreased, Metagenomi's cash and cash equivalents balance increased by $14.3 million in 2025, reaching $41.7 million at year-end. This marks a positive shift from 2024, when the cash balance decreased by $113.2 million. Let's examine the sources and uses of cash:
  • Cash from Day-to-Day Business (Operating Activities): This metric indicates the cash generated or consumed by Metagenomi's core business operations.
    • In 2025, operating activities consumed $88.9 million in cash.
    • This represents an improvement from 2024, when $109.1 million was consumed. While Metagenomi continues to spend more cash than it generates from core activities, the reduced burn rate indicates improved operational efficiency.
    • Important Note on Losses: Despite the reduced cash burn from operations, Metagenomi's net loss (the accounting measure of profit/loss) increased from $78.1 million in 2024 to $87.9 million in 2025. This divergence stems from non-cash expenses, such as stock-based compensation ($11.9 million in 2025, down from $16.2 million in 2024) and depreciation ($5.3 million in 2025, similar to 2024), which impact reported losses but not immediate cash outflow. A significant factor contributing to the reduced cash burn was a positive change in deferred revenue and collaboration advances, reflecting either increased revenue recognition or improved cash management related to these agreements.
  • Cash from Investments (Investing Activities): This category typically includes the purchase or sale of assets such as equipment and other investments.
    • In 2025, investing activities generated $103.5 million. This primarily resulted from the maturity or sale of marketable securities, which returned cash to the company. Specifically, Metagenomi received $170.5 million from maturing investments while spending $66.4 million on new ones.
    • This contrasts sharply with 2024, when investing activities consumed $88.2 million, largely due to the purchase of marketable securities ($306.1 million in new purchases versus $221.4 million from maturities).
  • Cash from Funding (Financing Activities): This section details how Metagenomi raises capital from investors or lenders.
    • In 2024, financing activities generated $84.0 million, primarily from the company's IPO, which involved selling new shares to the public.
    • In 2025, a minor outflow of $0.4 million occurred, mainly related to deferred costs and modest proceeds of $0.2 million from an employee stock purchase plan.
• Lease Commitments: Metagenomi has significant lease agreements for its offices and labs. As of December 31, 2025, total operating lease liabilities amounted to $40.7 million, with $6.0 million due within the next year.
• A Word from the Auditors: PricewaterhouseCoopers LLP, Metagenomi's independent auditors, issued a "clean opinion" on these financial statements. This indicates their belief that the financial figures are presented fairly and accurately, despite showing losses. However, the auditors specifically highlighted Metagenomi's recurring net operating losses and negative cash flows from day-to-day business activities in their report. This formal observation indicates that the company continues to spend more than it generates from core operations, raising questions about its ability to continue as a "going concern" without securing additional funding. While common for early-stage biotechnology companies, this is a critical point that management acknowledges and addresses, underscoring the need for future funding.

Assets, Liabilities, and Equity (Balance Sheet Snapshot)

The balance sheet provides a snapshot of Metagenomi's assets (what it owns), liabilities (what it owes), and stockholders' equity (what remains for shareholders) at a specific point in time.

• Total Assets: Metagenomi's total assets decreased from $324.6 million at the end of 2024 to $221.1 million at the end of 2025. This significant reduction largely resulted from the company's use of marketable securities to fund operations, as previously discussed.
• Total Liabilities: Conversely, total liabilities decreased from $89.7 million in 2024 to $62.5 million in 2025, indicating fewer outstanding debts or obligations compared to the prior year.
  • Deferred Revenue: Notably, 'deferred revenue' (money received for work not yet completed) significantly decreased from approximately $33.0 million (combining current and non-current portions) in 2024 to about $11.7 million in 2025. This reduction could signify increased revenue recognition during the year or fewer new upfront payments for future work. This trend warrants monitoring as it can influence future revenue.
• Accumulated Deficit: The 'accumulated deficit' stands out as a key figure for investors. This represents the cumulative total of all losses since the company's inception. It grew significantly from $223.0 million in 2024 to $310.9 million in 2025, clearly indicating that Metagenomi continues to operate at a substantial loss and consume capital as it develops its therapies. This reinforces the auditors' observation regarding ongoing net operating losses.
• Stockholders' Equity: Consequently, due to these accumulated losses and the decrease in assets, total stockholders' equity (the value belonging to shareholders) decreased from $234.9 million in 2024 to $158.6 million in 2025.

Key Risks to Consider Before Investing

Investing in a biotechnology company like Metagenomi involves specific risks that investors must understand:

• Clinical Development & Regulatory Approval Risk: Metagenomi's success depends on its ability to successfully develop and gain regulatory approval for its gene editing therapies. The drug development process is lengthy, expensive, and carries a high failure rate, with no guarantee that any product candidates will reach the market.
• Need for Future Funding & Dilution: Given its significant accumulated deficit and ongoing cash burn, Metagenomi will require substantial additional funding to continue operations and advance its pipeline. This could involve issuing more shares, which would dilute existing shareholder ownership, or incurring debt, which adds financial obligations.
• Reliance on Key Collaborations: A significant portion of Metagenomi's current revenue and future prospects relies on partnerships with companies like Moderna, Ionis, and AffiniT. Termination, delays, or unsuccessful outcomes of these collaborations could severely impact Metagenomi's financial health and ability to develop therapies.
• Intellectual Property (IP) Protection: Metagenomi's competitive advantage heavily relies on its proprietary gene editing technology. The ability to obtain, maintain, and enforce patents and other intellectual property (IP) rights is critical; challenges to its IP could undermine the business.
• Intense Competition: The gene editing and biotechnology landscape is highly competitive, with many larger, more established companies possessing greater resources also developing similar technologies and therapies.
• Early-Stage Company; No Approved Products: Metagenomi currently has no approved products generating sales revenue. Its business model is based on future product development and commercialization, which is inherently uncertain.
• Auditor's Going Concern Qualification: The auditors' note concerning Metagenomi's recurring losses and negative cash flows indicates a material uncertainty regarding the company's ability to continue as a going concern without additional funding. This constitutes a serious risk factor.

Competitive Position

Metagenomi operates within a highly dynamic and competitive landscape in the biotechnology and gene editing sectors. Its competitive position stems primarily from:

• Proprietary Gene Editing Platform: Metagenomi emphasizes its unique and diverse toolbox of gene editing systems, including various nucleases, base editors, and prime editors. This broad platform offers flexibility in targeting diverse genetic mutations and developing therapies for a wide range of diseases.
• Focus on In Vivo Applications and Delivery: A key differentiator is Metagenomi's strategic focus on in vivo gene editing, aiming to deliver therapies directly within the body. Its collaboration with Acuitas Therapeutics for LNP technology underscores its commitment to developing advanced and effective delivery mechanisms, which are crucial for successful in vivo gene editing.
• Strategic Collaborations: Partnerships with established pharmaceutical and biotechnology companies like Moderna, Ionis Pharmaceuticals, and AffiniT Therapeutics provide funding and validation, and leverage external expertise and resources, enhancing Metagenomi's ability to compete with larger entities.
• Intellectual Property: Metagenomi's ability to develop and protect its intellectual property surrounding its gene editing tools and delivery technologies is central to its competitive advantage.

The gene editing field is intensely competitive, featuring both publicly traded companies and private entities. Key competitors include:

• Other Gene Editing Companies: Companies such as CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Beam Therapeutics also develop gene editing therapies using various technologies (e.g., CRISPR-Cas9, base editing, prime editing).
• Large Pharmaceutical and Biotechnology Companies: Many established companies possess internal research programs or have acquired smaller gene therapy companies, bringing substantial financial, R&D, and commercialization resources to the market.
• Academic and Research Institutions: Universities and research centers also significantly contribute to gene editing innovation, often leading to new discoveries and potential competitors.

Competition hinges on factors such as the efficacy and safety profiles of product candidates, the breadth and strength of intellectual property portfolios, the ability to develop and scale manufacturing processes, access to capital, and the ability to attract and retain skilled scientific and management personnel. Metagenomi believes its diverse platform and strategic focus provide a strong foundation for competition but acknowledges the significant resources and advanced pipelines of many rivals.

What's Next? Strategy & Outlook

Metagenomi's strategy focuses on leveraging its proprietary gene editing platform to advance a pipeline of therapeutic candidates and secure its long-term future:

• Advance the Pipeline: Metagenomi plans to continue investing heavily in research and development to advance its lead programs through preclinical and clinical stages. This includes further optimizing its gene editing systems and expanding into new therapeutic areas.
• Expand Strategic Partnerships: Metagenomi aims to continue forging and expanding collaborations with pharmaceutical and biotechnology companies. These partnerships are crucial for sharing development costs, accessing specialized expertise, and potentially accelerating the path to market for its therapies.
• Platform Innovation: The company commits to ongoing innovation in its gene editing technology, including developing new delivery methods (such as through its Acuitas agreement) and expanding the capabilities of its gene editing tools.
• Prudent Capital Management: While acknowledging the need for future funding, management focuses on efficiently managing its current cash runway and exploring various financing options to support long-term growth without excessive dilution. Metagenomi aims to balance aggressive R&D with responsible financial stewardship.

Metagenomi is an early-stage biotechnology company with promising technology but also significant financial needs and inherent risks. Investors should carefully weigh these factors against the potential for groundbreaking medical advancements.